Glenmark bags USFDA approval for skin disease cream
The pharma company plans to commence the shipping of the product immediately.
New Delhi, January 28, 2013: Glenmark Pharmaceuticals has received the approval from the US health regulator to market Mupirocin Calcium Cream, used for treating skin diseases, in the US. Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd has been granted the final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Mupirocin Calcium Cream USP 2 per cent.
The company said in a statement that it plans to begin the shipping of the product on an immediate basis. It is worth mentioning here that Glenmark Generics Ltd (GGL) is a subsidiary of Glenmark Pharmaceuticals Ltd and has presence in various global markets including North America.
Mupirocin Calcium Cream is used for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S aureus and S pyogenes. Going by the IMS Health data, the product generates sales worth US$ 56.5 million for the 12-month period ending September 2012.